IL1A and diabetic kidney disease: People with diabetic nephropathy have elevated levels of both IL‐1β and IL‐1α in their serum,74, 75 with a recombinant human IL‐1 receptor antagonist (BLG‐553902) demonstrating efficacy in abrogating accumulation and deposition of fibrotic markers in PTECs.71